Valiant Laboratories Approves ₹81.47 Cr Rights Issue and Appoints New Company Secretary
By Shishta Dutta | Published at: Jul 9, 2025 04:07 PM IST
Mumbai, July 9, 2025 – Valiant Laboratories Ltd (NSE: VALIANTLAB | BSE: 543998) has announced a rights issue of fully paid equity shares worth up to ₹8,146.88 lakh. To execute the right issue, Valiant Laboratories has appointed Mr. Akshay Gangurde as Company Secretary and Compliance Officer in its board meeting held today.
Furthermore, the company has established a Rights Issue Committee to determine the key details of the issue, including the issue size, price, entitlement ratio, record date, and intermediaries.
The stock was trading at ₹116.20, up 1.68% as of 1:37 PM on July 9, 2025.
Key Resolutions from Board Meeting
1. Rights Issue of Equity Shares
The Board approved a capital raise via a rights issue of equity shares having a face value of ₹10 each. The total fundraise will not exceed ₹8,146.88 lakh.
|
Particulars |
Details |
|---|---|
|
Type of Security |
Fully paid-up equity shares |
|
Mode of Issue |
Rights Issue |
|
Maximum Issue Size |
₹8,146.88 lakh |
A Rights Issue Committee has been constituted to determine key terms such as issue size, price, entitlement ratio, record date, and intermediaries.
The issue will be in accordance with SEBI (ICDR) Regulations, 2018, SEBI LODR Regulations, Companies Act, 2013, and applicable laws.
“The Board has authorised a dedicated Rights Issue Committee to finalize all parameters,” the company stated in its filing.
2. Appointment of Company Secretary and Compliance Officer
Valiant Laboratories has appointed Mr. Akshay Gangurde (ICSI Membership No. A70561) as the Company Secretary and Compliance Officer, effective July 9, 2025. He is also designated as a Key Managerial Personnel (KMP) and Senior Management Personnel.
|
Particulars |
Details |
|---|---|
|
Name |
Akshay Gangurde |
|
Effective Date |
July 9, 2025 |
|
Qualification |
B.Com, LL.B, ACS (ICSI) |
|
Experience |
3+ years in secretarial and listing compliance |
|
Previous Employers |
S H Kelkar & Co, Saregama India, Makarand Joshi & Co. |
“He brings proven expertise in corporate governance and SEBI compliance,” the company stated.
Market Impact and Regulatory Context
The fundraising aligns with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and Listing Regulations under Regulation 30. The Rights Issue plan indicates the company’s intent to strengthen capital structure and support its future growth roadmap.
Outlook
Valiant Laboratories’ rights issue announcement and leadership appointment signal strategic growth planning. The move may boost investor sentiment as the capital raise is expected to support expansion goals, while regulatory alignment and governance upgrades enhance market confidence in near-term performance.
About the Company
Valiant Laboratories Ltd is listed on both NSE and BSE and is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), primarily Paracetamol. Headquartered in Mumbai, the company caters to domestic and international pharma clients. The company was listed in 2023 and has since focused on capacity expansion and backward integration.
REF:https://nsearchives.nseindia.com/corporate/VALIANT_09072025122303_BM_Outcome_9_July_2025.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
